Rouen University Hospital
Rouen, 76031, France
NCT Number: NCT02400853
The most frequent complications in premature infants are neurological complications: intracranial hemorrhages and white matter lesions. In Epipage 2 study the incidence of severe intraventricular hemorrhages remains stable. Severe hemorrhages are associated with neurological sequelae.
A recent study in humans and in animals shows the role of the complex formed by plasminogen activator (t-PA) and its inhibitor (PAI-1) in the induction of vascular fragility via stromelysin (MMP-3). FIBRINAT study in Rouen University Hospital showed a rate of complex t-PA-PAI1 probably very high in preterm infants. An other factor maturation PDGF-C induced by t-PA is associated with the vascular embrittlement. Among the few genetic factors associated with cerebral palsy include 2 SNP of PAI-1 gene and one SNP in the gene of endothelial NO synthase.
The hypothesis is that a high rate of the complex t-PA-PAI-1 in cord blood could be a high risk of intracranial hemorrhage in preterm infants and provide predictive of their occurrence. The rates of MMP-3, PDGF-C and PAI-1 free in cord blood, and the polymorphism of PAI-1 gene and eNOS could separately or associated with the main criterion to identify predictive of hemorrhages.
The main objective is to search a rate difference of the complex t-PA-PAI-1 in cord blood of preterm infants (before 30 weeks of gestation) that would predict intracranial hemorrhage coming in the first days of life.
The secondary objectives are
* Evaluate potential marker risk of high levels of MMP-3, PAI-1 free, and PDGF-CC * Search in both groups the presence of alleles -675G4 / G5 and 11053 (G / T) of the PAI-1 gene and -922 (A / G) of the eNOS gene.
120 preterm infants will be included before 30 weeks of gestation with precise inclusion and exclusion criteria during a period of 3 years.
Patients will be divided into two groups according to whether they will or not showed intracranial hemorrhage (detected by ultrasound J5-J7).
The complex rate tPA-PAI-1, PAI-1 free, MMP-3 and PDGF-C will be measured. The comparison between the two groups will be carried out using statistical tests. Comparison of the presence of the alleles -675 4G and 11053T the PAI-1 gene or -922G eNOS gene between the two groups will be performed.
The demonstration of this hypothesis would permit to identify children from birth in whom the immediate implementation of preventive treatment of bleeding is desirable.
Looking for future studies?
Notify Me1 day–1 day
All sexes
Interventional
Not applicable
Rouen, 76031, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
Cord blood will be collected during deliverance and analysed
Time frame: day 1
tPA-PAI-1 Complex rate in cord blood will be analysed in the 2 groups of infants
Time frame: day 1
MMP-3 rate in cord blood will be analysed in the 2 groups of infants
Time frame: day 1
PAI-1 rate in cord blood will be analysed in the 2 groups of infants
Time frame: day 1
PDGF-CC rate in cord blood will be analysed in the 2 groups of infants
Time frame: day 1
Polymorphism of specified sequence will be performed in the 2 groups of infants
Time frame: day 1
Polymorphism of specified sequence will be performed in the 2 groups of infants
University Hospital, Rouen
Other
Research a New Predictive Marker of Intraventricular Hemorrhage in Very Preterm Infants: HEMO PREMA Study
Acronym: HEMO PREMA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02814383
Brain Diseases, Brain Injuries
Houston, Texas, United States
View Trial DetailsNCT06043050
Blood Platelet Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Berlin, Metropolregion Berlin-Brandenburg, Germany
View Trial DetailsNCT05113381
Brain Diseases, Cardiovascular Diseases
Loma Linda, California, United States
View Trial DetailsNCT06256939
Intraventricular Hemorrhage
Cincinnati, Ohio, United States
View Trial Details